Semglee Side Effects

Semglee (insulin glargine-yfgn) is an interchangeable biosimilar of Lantus (insulin glargine), a long-acting form of insulin that helps people with diabetes manage their blood glucose levels.

Like other insulin products, Semglee may cause common side effects like low blood sugar, injection-site redness, weight gain, and fluid retention. Rare events include skin changes, allergic reactions, and vision issues.

Below, we’ll discuss each of these side effects, why they happen, how often they occur, and practical tips to prevent or manage them.

1. Hypoglycemia (low blood sugar)

Semglee contains insulin glargine, which helps move glucose from the bloodstream into the body’s cells. If the dose is too high or if meals, exercise, or other medications are not well balanced, blood sugar levels can drop too low.

Hypoglycemia is the most common adverse reaction associated with insulin therapy. In the INSTRIDE-1 trial, hypoglycemia occurred in 55% of patients taking Semglee and in 61% of patients receiving the reference insulin glargine. In INSTRIDE-2, it happened in 27.2% and 23.4% of patients, respectively.

Mild to moderate hypoglycemia is common when starting or adjusting insulin. Severe episodes are less common but require urgent attention.

How to recognize and manage low blood sugar

Low blood sugar often causes:

• • shakiness
  • sweating
  • a fast heartbeat
  • dizziness
  • hunger
  • irritability
  • anxiety

Some people also report blurred vision, tingling, headache, or confusion.

To treat mild hypoglycemia, consume a fast-acting carbohydrate such as glucose tablets, a small glass of fruit juice, or regular soda. Recheck your blood sugar after 15 minutes and repeat if it remains low. Always carry a quick sugar source with you.

For severe hypoglycemia (confusion, seizure, loss of consciousness), a caregiver should give a glucagon injection and call emergency services.

To prevent hypoglycemia, do not skip meals, monitor your blood glucose regularly, and work with your doctor to adjust your dose when your physical activity level or diet changes. Some medicines can increase the risk of hypoglycemia as well, including other diabetes medications, ACE inhibitors, and salicylates. So, talk to your provider about any new prescriptions or supplements.

2. Injection site reactions

Because Semglee is injected under the skin, local reactions at the injection site are relatively common. These include:

• • redness
  • pain
  • itching
  • hives (urticaria)
  • swelling (edema)
  • inflammation

These reactions occur because the body’s immune cells respond to the injected medication and the physical trauma of the needle. They are usually mild and temporary, but can be bothersome.

Tips to reduce and manage injection site reactions

To help minimize injection site reactions with Semglee, consider the following:

• • Rotate injection sites: Use different areas of your abdomen, thighs, or upper arms instead of injecting into the same spot every time.

• • Avoid problematic skin: Do not inject into areas with lumps, pits, thickened skin, or scar tissue.

• • Use proper technique: Clean the area with an alcohol swab and allow it to dry. Use a fresh needle for each injection. Keep the needle steady and inject at a consistent depth. Do not rub the injection site afterward. Instead, gently press the area for a few seconds.

• • Treat mild reactions: If redness or itching occurs, applying a cool compress can help. Over-the-counter anti-itch creams may provide relief, but check with your pharmacist first. Pain that persists or signs of infection (warmth, pus, increasing redness) should be evaluated by a healthcare provider.

3. Weight gain

Weight gain can occur with insulin therapy, including Semglee. This is because insulin has anabolic effects, meaning it helps the body store nutrients such as glucose and build tissues. This process can lead to an increase in body weight over time.

Strategies to manage weight gain

Here are some ways to help avoid gaining too much weight while using Semglee:

• • Monitor your diet: Work with a dietitian or diabetes educator to create a meal plan that matches your insulin dose and physical activity. Focus on nutrient-dense foods and limit high-calorie snacks.

• • Stay active: Regular physical activity helps burn calories and improves insulin sensitivity. Even moderate exercises like brisk walking or cycling can make a difference.

• • Check blood sugars regularly: Keeping glucose levels in the target range can prevent overeating caused by hypoglycemia. Avoid “defensive eating” (eating extra food to prevent low blood sugar) unless advised by your healthcare provider.

• • Discuss medication options: Some people take additional medications like metformin or GLP-1 receptor agonists that may help control weight. Talk with your doctor before adding or changing any medications.

4. Lipodystrophy and skin changes

Lipodystrophy refers to changes in the fat tissue under the skin at injection sites. Repeated injections into the same spot can cause the fat to shrink (lipoatrophy) or thicken (lipohypertrophy).

Studies suggest that lipodystrophy is less common today because of advances in needle technology and patient education.

How to prevent and manage lipodystrophy

Injecting into areas of lipodystrophy or localized cutaneous amyloidosis can lead to unpredictable insulin absorption and poor glycemic control. Here’s how to prevent it:

• • Rotate injection sites: This is the most important preventive step. Change (rotate) injection sites within the chosen area each time. That means picking a different spot at least a finger’s width away from the last injection.

• • Avoid problem spots: Do not inject into areas with pits, thickened skin, lumps, bruises, or scars.

• • Use proper equipment: Always use a new needle. Dull needles can increase tissue trauma.

• • Inspect your skin: Check your injection sites regularly for changes. If you notice lumps, dents, or discoloration, consult your healthcare provider. You may need to avoid injecting in that area until the skin returns to normal.

5. Peripheral edema (fluid retention)

Some people notice swelling in their hands, feet, or ankles soon after starting insulin, known as peripheral edema. Insulin can cause the kidneys to retain salt and water (fluid retention), leading to puffiness.

Peripheral edema is usually mild and transient. In a 5-year study of adults with type 2 diabetes, 20% of insulin glargine-treated participants experienced peripheral edema compared with 22.7% of those receiving NPH insulin.

Coping with swelling

Here are some tips on how to manage peripheral edema while on Semglee:

• • Monitor salt intake: Eating less sodium may reduce water retention. Avoid processed foods that are high in salt.

• • Stay active: Gentle exercise and elevating your legs can help improve circulation and reduce swelling.

• • Track your weight: Sudden weight gain can signal fluid retention. Weigh yourself daily and report rapid changes to your healthcare provider.

• • Medication review: If you take a thiazolidinedione (TZD), such as pioglitazone or rosiglitazone, your doctor may need to adjust or discontinue it to reduce the risk of fluid retention.

• • Seek medical attention: Severe or persistent swelling, especially if accompanied by shortness of breath, could indicate heart failure. Contact your doctor right away.

6. Allergic reactions

Mild allergic reactions involve local redness or itching at the injection site. These reactions usually occur soon after injection and go away on their own. However, severe allergic reactions, or anaphylaxis, are rare but can be life-threatening. Signs include:

• • difficulty breathing
  • rapid heartbeat
  • swelling of the face or throat
  • severe itching
  • generalized hives
  • a feeling of impending doom

Postmarketing surveillance data mention isolated cases of anaphylaxis, but the overall frequency is very low.

What to do if you suspect an allergic reaction

If you do suspect a possible allergic reaction, apply a cool compress to the site and monitor the area. If itching persists, ask your healthcare provider whether an antihistamine is appropriate.

For severe reactions, seek emergency medical attention immediately. Call emergency services, use an epinephrine auto-injector if you have one, and do not inject any more insulin until you have been evaluated by a doctor. They may recommend switching to a different insulin.

7. Hypokalemia (low potassium)

Insulin drives glucose into cells, and potassium follows along with it. As a result, blood potassium levels can drop after insulin administration. Hypokalemia may be life-threatening and is considered a serious side effect, which describes symptoms such as muscle weakness, cramps, and irregular heartbeat.

Hypokalemia is less common than hypoglycemia but can occur, especially in people taking medications that affect potassium, such as diuretics or beta-agonists. Patients with kidney disease, those on potassium-wasting diuretics, or those who experience prolonged vomiting or diarrhea may be more susceptible.

Preventing and managing hypokalemia

Hypokalemia is a potentially life-threatening condition and should be corrected promptly. The following measures may help reduce the risk:

• • Monitor potassium: Your doctor may order blood tests to check potassium levels, especially if you have risk factors.

• • Eat potassium-rich foods: Foods like bananas, oranges, tomatoes, potatoes, and spinach are good sources. However, talk with your healthcare provider before increasing potassium intake, especially if you have kidney problems.

• • Know the symptoms: Muscle cramps, weakness, heart palpitations, or numbness could signal low potassium. Report these symptoms promptly.

• • Medication review: Inform your doctor about all medications and supplements. Some drugs, such as diuretics, beta-agonists, and amphotericin B, can lower potassium levels.

8. Heart failure and fluid retention with TZDs

Thiazolidinediones (TZDs) such as pioglitazone (Actos) and rosiglitazone (Avandia) improve insulin sensitivity but are known to cause fluid retention. When combined with insulin therapy, the fluid-retaining effect can be amplified, increasing the risk of heart failure.

Heart failure associated with combined insulin and TZD therapy is relatively uncommon but serious. The risk is higher if you have existing heart disease or risk factors for cardiovascular disease.

Reducing the risk of heart failure

Let your healthcare provider know if you are taking or plan to take a TZD. They may reduce the dose or choose an alternative medication. Controlling blood pressure, limiting salt intake, and staying physically active can support heart health.

Rapid weight gain, swelling of legs or feet, and shortness of breath are warning signs. If these occur, contact your doctor immediately.

9. Eye problems

Some people notice changes in vision when starting insulin therapy. In clinical trials, upper respiratory tract infections, infections of unknown body systems, and eye disorders were among the most common non-metabolic adverse events.

A study in adults with type 2 diabetes reported retinal vascular disorder (a type of eye problem) in 5.8% of insulin glargine patients compared with 7.4% of those on NPH insulin. In a long-term study, cataract was also slightly more common in the insulin glargine group than in the NPH group (18.1% vs. 15.9%).

Blurred vision and changes in focus can also occur when blood sugar levels fluctuate. Vision often improves as blood glucose stabilizes. However, sudden vision loss, severe eye pain, or seeing halos around lights could indicate serious problems such as retinopathy or macular edema and require prompt medical evaluation.

10. Immunogenicity and antibody formation

Immunogenicity refers to the potential of a therapeutic protein to trigger an immune response. All biological products can stimulate the immune system to produce antibodies against the drug, which may neutralize its effect or cause side effects.

For most people, antibodies against insulin glargine do not cause noticeable problems. However, if antibody titers are high, insulin may be absorbed unpredictably, leading to unexplained highs or lows.

Your doctor might order blood tests to check for antibodies if your glucose control becomes erratic without an obvious reason. In practice, clinically significant immunogenicity is uncommon with modern insulin therapies.

In clinical trials, Semglee has a similar immune response (immunogenicity) to reference insulin glargine 100 U/mL in patients with type 1 and type 2 diabetes, including those who switch between the two.

The numbers are very close across all studies, showing that Semglee and reference insulin glargine have no meaningful differences in immune response.

Tips to minimize immunogenicity concerns

There is no way to prevent antibody formation completely. The best approach is to:

• • Use insulin consistently: Follow your prescribed dose and schedule. Inconsistent dosing can confuse the immune system.

• • Store the insulin properly: Insulin that has been exposed to extreme temperatures or expired may degrade and increase the risk of immune reactions.

• • Discuss unexplained fluctuations: If your blood sugar becomes unstable despite adherence, talk to your healthcare provider about potential antibody testing.

Bottom line

Semglee offers an affordable, interchangeable alternative to Lantus for people with diabetes. Its safety profile closely matches that of the reference insulin glargine. The most common side effect is low blood sugar, injection site reactions, weight gain, lipodystrophy, and swelling. Most side effects are mild and manageable, and serious reactions are rare. If you experience unusual or severe symptoms, seek medical attention promptly.

Frequently Asked Questions

Sources

Blevins, T. C., Barve, A., Sun, B., & Ankersen, M. (2018). Efficacy and safety of MYL?1501D vs insulin glargine in patients with type 1 diabetes after 52?weeks: Results of the INSTRIDE 1 phase III study. Diabetes Obesity and Metabolism, 20(8), 1944–1950. https://doi.org/10.1111/dom.13322

Blevins, T. C., Barve, A., Sun, B., Raiter, Y., Aubonnet, P., Muniz, R., Athalye, S., & Ankersen, M. (2018). Efficacy and safety of MYL?1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study. Diabetes Obesity and Metabolism, 21(1), 129–135. https://doi.org/10.1111/dom.13495

Hoy SM. MYL1501D Insulin Glargine: A Review in Diabetes Mellitus. BioDrugs. 2020 Apr;34(2):245-251. doi: 10.1007/s40259-020-00418-x. Erratum in: BioDrugs. 2020 Aug;34(4):541. doi: 10.1007/s40259-020-00426-x. PMID: 32215829; PMCID: PMC7217807.

FDA. (2023). HIGHLIGHTS OF PRESCRIBING INFORMATION OF SEMGLEE. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761201s010lbl.pdf

Matli, M. C., Wilson, A. B., Rappsilber, L. M., Sheffield, F. P., Farlow, M. L., & Johnson, J. L. (2021). The first interchangeable biosimilar insulin: insulin glargine-YFGN. Journal of Diabetes Science and Technology, 17(2), 490–494. https://doi.org/10.1177/19322968211067511